There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Labs (ABT – Research Report) and Elevance Health (ELV – Research Report) with bullish sentiments.
Abbott Labs (ABT)
In a report released yesterday, Lee Hambright from Bernstein maintained a Buy rating on Abbott Labs, with a price target of $133.00. The company’s shares closed last Thursday at $105.27.
According to TipRanks.com, Hambright is a 4-star analyst with an average return of
Currently, the analyst consensus on Abbott Labs is a Strong Buy with an average price target of $127.67, representing a 19.9% upside. In a report issued on April 3, Citi also maintained a Buy rating on the stock with a $128.00 price target.
See the top stocks recommended by analysts >>
Elevance Health (ELV)
J.P. Morgan analyst Lisa Gill maintained a Buy rating on Elevance Health yesterday. The company’s shares closed last Thursday at $525.19.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Elevance Health with a $579.89 average price target, which is an 11.4% upside from current levels. In a report issued on April 8, Wells Fargo also maintained a Buy rating on the stock with a $557.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABT:
